Avidity biosciences announces updates on the pipeline and platform at virtual investor and analyst event

La jolla, calif., may 19, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called antibody oligonucleotide conjugates (aocs™), announced that new preclinical data on its lead aoc program, aoc 1001, and key programmatic updates will be shared at a virtual investor and analyst event today.
RNA Ratings Summary
RNA Quant Ranking